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Abstract
There is evidence to suggest that abnormal angiogenesis, inflammation, and fibrosis drive
diabetic nephropathy (DN). However, there is no specific treatment to counteract these pro-
cesses. We aimed to determine whether DIAVIT, a natural Vaccinium myrtillus (blueberry)
and Hippophae Rhamnoides (sea buckthorn) extract, is protective in a model of type II DN.
Diabetic db/db mice were administered DIAVIT in their drinking water for 14 weeks. We
assessed the functional, structural, and ultra-structural phenotype of three experimental
groups (lean+vehicle, db/db+vehicle, db/db+DIAVIT). We also investigated the angiogenic
and fibrotic pathways involved in the mechanism of action of DIAVIT. Diabetic db/db mice
developed hyperglycaemia, albuminuria, and an increased glomerular water permeability;
the latter two were prevented by DIAVIT. db/db mice developed fibrotic glomeruli, endothe-
lial insult, and glomerular ultra-structural changes, which were not present in DIAVIT-treated
mice. Vascular endothelial growth factor A (VEGF-A) splicing was altered in the db/db kid-
ney cortex, increasing the pro-angiogenic VEGF-A165 relative to the anti-angiogenic VEGF-
A165b. This was partially prevented with DIAVIT treatment. Delphinidin, an anthocyanin
abundant in DIAVIT, increased the VEGF-A165b expression relative to total VEGF-A165 in
cultured podocytes through phosphorylation of the splice factor SRSF6. DIAVIT, in particu-
lar delphinidin, alters VEGF-A splicing in type II DN, rescuing the DN phenotype. This study
highlights the therapeutic potential of natural drugs in DN through the manipulation of gene
splicing and expression.
Introduction
Diabetic nephropathy (DN) is the leading cause of end stage renal disease (ESRD) in the USA
and across the world, affecting 50% of diabetic patients [1–3]. Glycaemic control, lipid and
blood pressure control, plus renin-angiotensin-aldosterone system (RAAS) blockade are the
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current treatments of choice [4], but many DN patients still progress to ESRD. Therefore,
novel therapeutic approaches for the treatment of DN are required.
In DN, alterations of the glomerular filtration barrier (GFB) result in increased permeability
to protein; such changes include glomerular basement membrane (GBM) thickening, mesan-
gial matrix expansion (MME), podocyte detachment, and glomerular endothelial cell damage
[5,6]. An increasing number of studies suggest that angiogenesis, inflammation, and fibrosis
are responsible for the onset of type II DN [7,8]. Abnormal expression of vascular endothelial
growth factor A (VEGF-A) in the kidney has been widely reported in DN [9–10]. Alternative
splicing of exon 8 of VEGF-A results in an anti-angiogenic splice isoform, VEGF-A165b [11],
which is protective in DN and renal disease [7,12]. In addition, activation of the transcription
factor p65 nuclear factor kappa B (p65-NFĸB) is linked to the regulatory pathways that under-
lie the pro-inflammatory and pro-fibrotic response [13], and an increase in p65-NFĸB translo-
cation to the nucleus has been shown in human DN [14].
In diabetes, glucotoxicity results in the generation of free radicals and oxidative stress, lead-
ing to the progression of diabetic complications [15]. Activation of NFĸB is widely reported to
be evoked by increased oxidative stress [16]. Previous studies in rodent models of DN have
indicated that a reduction in oxidative stress using anti-oxidants, such as those found in red
berry extracts, resulted in decreased NFĸB activity, thus improving kidney function [17,18].
Other studies have also found that berry/polyphenol rich extracts protect against fibrosis,
angiogenesis, and inflammation in the kidneys of diabetic animal models [19–21].
DIAVIT is a natural drug based on polyphenol-rich blueberry (Vaccinium myrtillus) and
sea buckthorn (Hippophae Rhamnoides), which has been approved as an adjunct therapy for
diabetes in Romania. DIAVIT contains approximately 10 mg anthocyanins per gram, which
have been previously described to decrease vessel permeability, improve microcirculation and
exert antioxidant activity [22,23]. The most abundant is delphinidin, which has been previ-
ously reported to have potent anti-angiogenic properties through the inhibition of PI3K/Akt/
mTOR signaling pathways [24,25].
The aim of the present study was to test the hypothesis that DIAVIT would have a beneficial
effect on the phenotype of diabetic renal lesions in the db/db mouse model of type II DN. Fur-
thermore, we aimed to determine by which mechanism DIAVIT was exerting a protective
effect by investigating pathways linked to the pro-angiogenic and pro-fibrotic response, as well
as assessing the mechanistic effect of the most abundant anthocyanin present in DIAVIT, del-
phinidin, on the expression and splicing of VEGF-A.
Materials and methods
Ethics approval
All experiments and procedures were approved by the UK Home office in accordance with the
Animals (Scientific Procedures) Act 1986, and the Guide for the Care and Use of Laboratory
Animals was followed.
Administration of DIAVIT
DIAVIT tablets (1 g) were obtained from Plantarom Laboratories, Cluj, Romania (Lot: 01,
Expiry: January 2017). One tablet was ground to a fine powder and dissolved into 250 ml of
drinking water. This dose was equivalent to the highest recommended daily dose of DIAVIT
per kg body weight in patients, which equated to approximately 6 g/kg/day. The water was
changed three times weekly. Lean and non-diabetic db/db mice consumed approximately 5 ml
water per day, whereas diabetic mice consumed up to 60 ml per day, depending of the severity
of diabetes. Information regarding the extract dosage of DIAVIT can be found in Table 1. We
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performed gas chromatography and mass spectrometry (GC-MS) to determine the complex
chemical composition of the extract (S1 Fig). A large part of the extract in the DIAVIT tablets
are dried blueberries from Romania—the composition of the extracts from these blueberries,
especially anthocyanins content, has been extensively analysed before [26, 27].
Animal functional studies
Male BKS.Cg-+Leprdb/+Leprdb/OlaHsd (db/db; obtained from Envigo) and lean control mice
were obtained from Envigo (UK) (5 weeks; 25–49 g). Blood glucose was measured via blood
collection from the tail vein, which was applied to an ACCU-CHEK strip (ACCU-CHEK,
Roche) to determine the concentration in mmol/l. Mice were deemed diabetic if they had two
consecutive blood glucose readings >15 mmol/l taken 48 h apart. Baseline urine, weight, and
blood glucose measurements were taken at 6 weeks of age, and DIAVIT administration into
the drinking water began immediately after. Urine collection, blood glucose measurement,
and animals weights were done every week up until 20 weeks of age (week 14 of experiment),
when they were killed. There were three groups of mice; lean (n = 6), db/db (n = 9), and db/db
treated with DIAVIT (n = 9). Statistical power calculations showed that six control and eight
experimental mice were needed to see a statistical difference in the functional phenotype
(p>0.05) with a power value of 0.80 (>80%).
The urinary albumin creatinine ratio (uACR) was used as a measure of protein loss in the
urine. Albumin was quantified with an albumin ELISA (Bethyl Laboratories, Inc), and creati-
nine with an enzymatic spectrophotometric assay (Creatinine Companion, Exocell). Assays
were repeated in triplicate for each time point. Upon culling of mice via cervical dislocation,
blood was collected for plasma creatinine measurements (Creatinine Companion, Exocell).
Kidneys were removed and part of the cortex was immediately diced into 1 mm3 pieces and
fixed in 2.5% gluteraldehyde in 0.1 M cacodylate buffer for electron microscopy (EM). Pieces
of kidney cortex were also fixed in 4% paraformaldehyde (PFA), snap frozen in embedding
medium (OCT), and snap frozen in liquid nitrogen before storing at -80˚C for RNA and
protein analysis at a later date. The remaining kidney was used to harvest glomeruli, using a
standard sieving technique, for use an oncometric assay to determine the glomerular water
permeability normalised to glomerular area (LpA/Vi) of individual glomeruli ex vivo [28]. LpA/
Vi experiments were carried out on 6 mice per group, 3–5 glomeruli per mouse.
Structural and ultra-structural phenotype
PFA-fixed kidney cortex was sectioned at 5 μm thickness and stained with Periodic Acid Schiff
(PAS) and Masson’s Trichrome Blue stain (both Sigma). Sections were imaged on a light
microscope and experiments were repeated three times on 4 mice per group.
The ultra-structural phenotype was determined by post-fixation of the glutaraldehyde-fixed
diced kidney cortex with 1% osmium tetroxide, before embedding in Araldite (Agar Scien-
tific). Sections were cut at 50-100nm thickness and stained with 3% aqueous uranyl acetate
and Reynolds’ lead citrate solution. After images were taken, detailed measurements of the fil-
tration barrier were taken by a blinded experimenter at random points using ImageJ. Measure-
ments included GBM width, number of endothelial fenestrations and podocyte foot processes
Table 1. Dietary dosage of DIAVIT.
DIAVIT composition Per tablet (mg) Daily dosage (g/kg)
Vaccinium myirtillus 392 2.35
Hippophae rhamnoides 167 1.00
https://doi.org/10.1371/journal.pone.0212910.t001
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per μm length, and average podocyte foot process width. We also assessed whether there was
evidence of glomerular MME.
Cell culture studies
Mycoplasma-free immortalized human podocytes (hTERT; Evercyte) were plated in to 12-well
plates before treating for 48 hrs with DIAVIT (1 mg/ml in 1xPBS) or delphinidin chloride
(Sigma Aldrich) (10 μg/ml in DMSO). A dosage of 1 mg/ml DIAVIT was chosen because this
equated to an anthocyanin concentration of approximately 10 μg/ml, of which delphinidin is
the most abundant in the extract, which has been shown to have anti-angiogenic properties in
previous studies [25].
To determine the effect of delphinidin on the phosphorylation of SR proteins, podocytes
were serum starved for 2 hrs before treating with delphinidin chloride (10 μg/ml), or DMSO
control for a further 2 hrs. Cells were then stimulated with a diabetic soup (30 mM Glucose, 1
ng/ml TNFα, 1 ng/ml IL-6, and 100 nM insulin) or an osmotic control (5mM Glucose + 25
mM Mannitol) for 0.5 or 1 hrs, before extracting the protein.
Matrigel angiogenesis assay
Podocytes were treated with either DIAVIT (1 mg/ml) or DIAVIT plus anti-VEGF-A165b
(1 μg/ml), or delphinidin chloride (10 μg/ml) or delphinidin plus anti-VEGF-A165b (1 μg/ml)
for 48 hrs. IgG was added to controls. The conditioned media was then used to treat human
umblical vein endothelial cells (HUVECs) plated onto Matrigel. The wells were imaged 4 hrs
later and the tubule length and number of branch points were quantified.
Immunofluorescence
Frozen kidney cortex was sectioned at 5 μm thickness, mounted on to glass slides, and fixed
for 10 min with 4% PFA before washing in PBS. Sections were blocked with 3% bovine serum
albumin (BSA) and 5% normal goat serum in PBS for 1 hr before incubating with the primary
antibody (anti-collagen IV or anti-fibronectin, 1:100, Abcam; anti-nephrin, 1:250, Acris; anti-
podocin, 1:250, Sigma; anti-PECAM-1, 1:100, BD Bioscience) diluted in 3% BSA in PBS at 4˚C
overnight. After washing in PBS, the appropriate fluorescent secondary antibody was used
(Alexa Fluor) in 3% BSA in PBS for 2 hr at room temperature. Sections were then washed in
PBS before staining with DAPI and mounting with coverslips. Glomeruli and cortex were
imaged using a fluorescent microscope. Experiments were repeated three times on 3–4 mice
per group.
Western blotting
Denatured protein samples were run on mini-PROTEAN TGX Stain Free pre-cast gels (4–
15%, BIORAD), which allow for visualisation and accurate analysis of the total protein loaded
for each sample using a Gel-Doc EZ (BIO-RAD) imaging system. The use of this system
means a housekeeping protein loading control is not required as the amount of protein on the
membrane for each sample can be quantified. Once protein had been transferred on to a
PVDF membrane, total protein could be quantified. Membranes were blocked in 3% BSA in
TBS plus 0.3% Tween before being probed with either anti-collagen IV (Abcam), anti-fibro-
nectin (Abcam), anti-nephrin, Acris), anti-podocin (Sigma), anti-VEGF receptor 2 (VEGFR2)
(Cell Signalling), anti-VEGF A20 (Santa Cruz), anti-mVEGF-A165b (Prof Kenneth Walsh, Bos-
ton University), anti-phospho-AktSer473 (Cell Signalling), anti-Akt (Cell Signalling), anti-phos-
pho-extracellular signal-related kinase 1/2 (ERK1/2) (Cell Signalling), anti-ERK1/2 (Cell
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Signalling), anti- cyclooxygenase 2 (COX-2) (Cell Signalling), anti-wilms tumor 1 (WT1)
(Abcam), anti-p65-nuclear factor kappa B (NFĸB) (Cell Signalling), anti-SR proteins 1H4
(Santa Cruz), and anti-phospho-SR proteins (mab104), all at 1:1000 dilution in 3% BSA-TBS-
Tween (0.3%), at 4˚C overnight. After washing membranes in TBS-Tween (0.3%), HRP-conju-
gated secondary antibodies were diluted in 3% BSA-TBS-Tween (0.3%), 1:10,000. Membranes
were washed again and imaged using ECL detection agent (BIO-RAD) on an Amersham
imager. The protein of interest was then normalised to the total protein loaded for each sam-
ple, as quantified by the Gel-Doc EZ imaging system (BIO-RAD). Experiments were repeated
on at least three biological repeats, with the relative controls run on the same blot.
Statistical analysis
We performed statistical analysis using GraphPad Prism software. Data was tested for normal-
ity and either a one-way or two-way ANOVA was used to analyse data sets. Post-hoc analysis
was then carried out using the Bonferroni test for comparison between pairs. All results are
presented as the average ± standard error of the mean (SEM). Imaging and analysis was
blinded to the researcher to restrict bias. Details of biological and technical repeats can be
found in the methods section. P values<0.05 were considered statistically significant.
Throughout the manuscript, � indicates a significant different between lean mice and db/db
mice and † indicates a significant difference between db/db mice and db/db + DIAVIT mice,
as determined by a one-way ANOVA with Bonferroni post-hoc test.
Results
DIAVIT is protective against diabetes-induced increases in glomerular
water permeability and albuminuria
Both db/db and db/db + DIAVIT mice developed and maintained a significant increase in
their blood glucose levels one week after beginning of the study, compared to lean controls
(Fig 1A; blood glucose averaged over 14 weeks: 8.29 ± 0.08, 24.54 ± 1.23, and 21.83 ± 1.28
mmol/l in lean, db/db, and db/db + DIAVIT mice, respectively). There was no significant dif-
ference in blood glucose levels between the db/db and db/db + DIAVIT groups. However,
DIAVIT treatment did prevent the progressive increase in albuminuria observed in db/db
mice (Fig 1B; uACR (μg/mg) at 14 weeks: lean, 12.8 ± 1.2 μg/mg; db/db, 312.3 ± 154.4 μg/mg;
db/db + DIAVIT, 138.7 ± 19.4 μg/mg; values normalized to baseline shown in S2 Fig). Further-
more, the water permeability of individual glomeruli ex vivo was significantly increased in db/
db mice after 14 weeks of elevated blood glucose compared to lean controls (Fig 1C; �p<0.05).
This was significantly prevented in db/db + DIAVIT glomeruli (†p<0.05). Although db/db
mice developed type II diabetes and albuminuria, no changes in the plasma creatinine levels
were observed (Fig 1D). Therefore, DIAVIT protected against increases in glomerular water
permeability and albuminuria in type II diabetic mice without altering glycaemia.
DIAVIT prevents the development of diabetes-induced renal fibrosis
After 14 weeks of DIAVIT treatment the structural phenotype was assessed. PAS staining indi-
cated some MME and the development of vacuoles within the glomeruli of db/db mice (Fig
2A), which appeared to be reduced when db/db mice had been treated with DIAVIT. In addi-
tion, Trichrome blue staining showed an increase in collagen (blue) deposition in the glomer-
uli and cortex of db/db kidneys (Fig 2A), which also appeared to be reduced in db/db +
DIAVIT mice. To quantify the extent of glomerular fibrosis, we carried out immunofluores-
cence for collagen IV and fibronectin; two proteins highly expressed in a fibrotic kidney
DIAVIT extract to treat diabetic nephropathy
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(Fig 2A). Both collagen IV and fibronectin expression were increased in the glomeruli of dia-
betic db/db mice compared to lean controls (Fig 2B; �p<0.05). However, they were signifi-
cantly reduced in DIAVIT-treated db/db glomeruli (†p<0.05).
The increase in kidney fibrosis observed in db/db mice was further assessed by Western
blotting of kidney cortex proteins for collagen IV and fibronectin. The relative expression of
both proteins was increased in db/db kidneys compared to lean controls (�p<0.05), which was
significantly prevented in db/db + DIAVIT kidneys (†p<0.05) (Fig 2C, 2D and 2E). Therefore,
DIAVIT protects against renal fibrosis in a type II model of diabetes.
DIAVIT protects against the endothelial damage caused by type II diabetes
In order to assess how DIAVIT is protective in type II DN, we determined the expression of
podocyte and endothelial-specific proteins as markers of cell function/loss. Immunofluores-
cence for the podocyte markers nephrin and podocin indicated no changes in the expression
of these two proteins in any of the groups (Fig 3A); therefore, suggesting no podocyte loss.
This was further confirmed by Western blotting of protein from the kidney cortex (Fig 3B
and 3C).
Fig 1. DIAVIT prevents albuminuria and increased glomerular water permeability in diabetic db/db mice, whilst
having no effect on blood glucose. A) db/db mice develop increased blood glucose at 6–7 weeks of age (week 1 of
treatment), compared to lean controls (�p<0.05), which is not affected by DIAVIT consumption (ns; p>0.05; n = 6–9
mice; Two-way ANOVA based on the average values over 14 weeks). B) When assessing the urinary albumin
creatinine ratio (uACR), db/db mice develop progressive albuminuria at 10 weeks of age (week 4 of treatment),
compared to lean controls (�p<0.05), which is significantly rescued by DIAVIT (†p<0.05; n = 6–9 mice; Two-way
ANOVA based on the average values over 14 weeks). C) Glomeruli from db/db mice have an increased glomerular
water permeability (LpA/Vi) when compared to lean control glomeruli (
�p<0.05), which is significantly rescued in
glomeruli from DIAVIT-treated db/db mice (†p<0.05; n = 6 mice, 15–25 glomeruli; One-way ANOVA with
Bonferroni post-hoc test for comparison between pairs). D) Plasma creatinine levels remained unchanged between
groups (ns; p>0.05; n = 6–9 mice; One-way ANOVA with Bonferroni post-hoc test for comparison between pairs).
https://doi.org/10.1371/journal.pone.0212910.g001
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Immunofluorescence for the endothelial marker PECAM-1 showed reduced expression in
db/db glomeruli relative to lean controls (Fig 3D and 3E; �p<0.05). This was significantly pre-
vented in db/db + DIAVIT glomeruli (†p<0.05). Further evidence for endothelial loss in db/
db glomeruli was indicated by reduced protein expression of VEGFR2 in the cortex of db/db
mice, as assessed by Western blotting, relative to lean controls (Fig 3F and 3G;�p<0.05). The
reduction in VEGFR2 expression was prevented, and even significantly increased relative to
controls in the db/db + DIAVIT kidney cortex (†p<0.05). Therefore, DIAVIT prevented the
type II diabetes-induced reduction in renal endothelial markers.
DIAVIT protects against ultra-structural changes
We investigated the glomerular ultra-structural phenotype using EM. In diabetic db/db mice,
there was evidence of MME, which was not apparent in db/db + DIAVIT glomeruli (Fig 4A).
Fig 2. Diabetic db/db mice develop glomerular fibrosis, which is prevented in DIAVIT treated db/db mice. A)
Periodic Acid Schiff (PAS) staining indicated structural abnormalities in db/db glomeruli, including mesangial matrix
expansion and the presence of vacuoles (scale bar 40 μm). These appeared to be less frequent in DIAVIT-treated db/db
glomeruli. Trichrome blue staining showed an increase in fibrosis (blue collagen staining) in the db/db kidney cortex,
which was lower in the DIAVIT-treated db/db kidneys (scale bar 40 μm). More specifically, immunofluorescence for
collagen IV and fibronectin showed an increase in glomerular fibrosis in db/db mice, compared to lean controls, which
was prevented by DIAVIT treatment of the diabetic mice (quantified in B; �p<0.05 lean vs db/db; †p<0.05 db/db vs
db/db + DIAVIT; n = 4 mice; 15–20 glomeruli per mouse; One-way ANOVA with Bonferroni post-hoc test for
comparison between pairs; scale bar is 40 μm). C) Western blotting of protein from the kidney cortex confirms an
increase in the protein expression of collagen IV and fibronectin in db/db mice, which is prevented with DIAVIT
treatment. Analysis of the Western blots is summarised in D and E (�p<0.05 lean vs db/db; †p<0.05 db/db vs db/db +
DIAVIT; n = 3–4 mice; One-way ANOVA with Bonferroni post-hoc test for comparison between pairs).
https://doi.org/10.1371/journal.pone.0212910.g002
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In addition, db/db mice developed an increased GBM width, loss of endothelial fenestrations,
reduced number of podocyte foot processes, and an increased podocyte foot process width
(Fig 4B and 4E; �p<0.05). However, in db/db + DIAVIT glomeruli, the diabetes-induced
changes in the GBM, number of endothelial fenestrations, and podocyte foot process width
were prevented (†p<0.05). Therefore, DIAVIT protects against diabetes-induced glomerular
ultra-structural changes.
Fig 3. Diabetic db/db mice develop an endothelial insult, which is prevented by DIAVIT treatment of diabetic db/
db mice. A) Immunofluorescence for nephrin and podocin showed no change in the expression of these podocyte
markers between all groups (n = 4 mice; scale bar 40 μm). This was confirmed by Western blotting of protein extracted
from the kidney cortex (B); analysis is summarised in (C) (ns; p>0.05; n = 3–4 mice; One-way ANOVA with
Bonferroni post-hoc test for comparison between pairs). D) Immunofluorescence for the endothelial marker PECAM-
1 showed a reduction in PECAM-1 expression in db/db glomeruli, which was prevented when db/db mice were treated
with DIAVIT; analysis shown in (E) (�p<0.05 lean vs db/db; †p<0.05 db/db vs db/db + DIAVIT; n = 3–4 mice; 14–20
glomeruli per mouse; One-way ANOVA with Bonferroni post-hoc test for comparison between pairs; scale bar
40 μm). F) Western blotting for the endothelial marker VEGF receptor 2 (VEGFR2) showed a decrease in the db/db
kidney cortex, further indicating endothelial loss, which was prevented, and even increased relative to controls, in
DIAVIT-treated db/db mice. Analysis is shown in (G) (�p<0.05 lean vs db/db; †p<0.05 lean and db/db vs db/db +
DIAVIT; n = 3–4 mice; One-way ANOVA with Bonferroni post-hoc test for comparison between pairs).
https://doi.org/10.1371/journal.pone.0212910.g003
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Fig 4. DIAVIT protects against diabetes-induced glomerular ultra-structural changes. A) Representative
glomerular electron micrographs from lean, db/db, and db/db + DIAVIT mice. Diabetic db/db glomeruli shows
evidence of MME, which is not apparent in lean or db/db + DIAVIT glomeruli. Diabetic db/db glomeruli developed
an increased GBM width (B), decreased number of endothelial fenestrations (C) and podocyte foot processes (D)
per μm length, and an increased average podocyte foot process width (E) compared to lean controls (�p<0.05 vs lean).
DIAVIT prevented the changes to the GBM width (B), number of endothelial fenestrations per μm length (c), and
average podocyte foot process width (E) in db/db + DIAVIT glomeruli (†p<0.05 vs db/db). DIAVIT had no effect on
the podocyte foot processes per μm length (D) (�p<0.05 vs lean) (n = 3 mice; One-way ANOVA with Bonferroni post-
hoc test for comparison between pairs).
https://doi.org/10.1371/journal.pone.0212910.g004
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DIAVIT alters VEGF-A splicing
We assessed the protein expression of VEGF-A, which is also highly implicated in DN, and the
alternatively spliced anti-angiogenic isoform VEGF-A165b. Treatment of conditionally immor-
talized podocytes with DIAVIT (1 mg/ml) for 48 hrs resulted in a splicing switch to increase
the protein expression of VEGF-A165b relative to total VEGF-A165 (Fig 5A, quantified in Fig
5Bi; �p<0.05), with no effect on pan-VEGF-A expression (Fig 5Bii). We also saw a significant
increase in the VEGF-Axxxb/VEGF-Axxx ratio at the mRNA level via RT-PCR, quantified using
a bioanalyzer (Fig 5C). Therefore, we assessed the effects of DIAVIT on angiogenesis using a
Matrigel angiogenesis assay. HUVECs were plated onto Matrigel and treated with conditioned
media from podocytes pre-treated with DIAVIT for 48 hrs. Four hours later, DIAVIT-treated
HUVECs had a reduction in the relative number of branch points and the relative tubule
length (Fig 5D and 5E; �p<0.05), compared to untreated controls. This anti-angiogenic effect
was significantly reversed when the podocytes and HUVECs were treated with DIAVIT and
an antibody specific for the VEGF-A165b isoform (†p<0.05).
When analyzing the splicing pattern of VEGF-A in the kidney cortex of diabetic db/db
mice, there was a significant increase in the relative expression of VEGF-A120, which was not
observed in DIAVIT-treated db/db mice (Fig 5F and 5G; �p<0.05). An increase in the expres-
sion of VEGF-A164 (which corresponds to human VEGF-A165) was also observed in both dia-
betic groups relative to lean controls (�p<0.01). No changes in the expression of VEGF-A188
was observed in either group. When looking specifically at the splicing VEGF-A164, the anti-
angiogenic VEGF-A165b (alternatively spliced isoform of VEGF-A164) was down-regulated
in the db/db kidney cortex relative to lean controls (�p<0.05). This was partially prevented
when the db/db mice were treated with DIAVIT (†p<0.05). Therefore, DIAVIT switches
VEGF-A165/164 splicing to increase the anti-angiogenic VEGF-A165b isoform.
The expression of the transcription factor WT1, which promotes VEGF-A165b splicing [25],
remains unchanged in the kidney cortex in diabetic db/db mice relative to controls; however,
DIAVIT treatment induced a significant increase in WT1 expression (Fig 5H and 5I; relative
expression: db/db + DIAVIT, �p<0.05).
DIAVIT prevents the activation of pro-angiogenic and pro-fibrotic factors
To further assess the effects of DIAVIT on the diabetic kidney, we looked at the activation of
pro-angiogenic/permeability factors known to be involved in the progression of DN. We
found the phosphorylation of AktSer473 and ERK1/2, normalized to total Akt and ERK1/2,
respectively, to be increased in the kidney cortex of diabetic db/db mice (�p<0.01); the relative
expression of Akt, ERK1/2 and COX-2 was also increased (Fig 6A, 6B, 6C and 6D; �p<0.05).
All of the above was prevented in diabetic db/db + DIAVIT mice (†p<0.05) (Fig 6A, 6B, 6C
and 6D).
We also assessed the effects of DIAVIT on the protein expression and activation of
p65-NFĸB, which is involved in pro-fibrotic gene transcription [13]. In the db/db kidney cor-
tex, after 14 weeks of diabetes, there was a significant increase in the protein expression of
p65-NFĸB, relative to lean controls (Fig 6E and 6F; �p<0.05). This increase in p65-NFĸB was
prevented by DIAVIT treatment of the diabetic db/db mice (†p<0.05).
Delphinidin alters the expression and splicing ratio of VEGF-A in
podocytes
We further assessed the mechanistic effects of the most abundant anothocyanin in DIAVIT,
delphinidin, on VEGF-A splicing and expression. Treatment of conditionally immortalized
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Fig 5. DIAVIT alters VEGF-A splicing to increase VEGF-A165b. A) DIAVIT treatment (1 mg/ml) of podocytes for
48 hrs resulted in an increased protein expression of VEGF-A165b relative to total VEGF-A165 (quantified in B;
�p<0.05; n = 3 biological repeats; T-test; A—the same blot was first probed with VEGF-A165b before stripping and
reprobing with panVEGF-A). C) This switch in splicing to increase the VEGF-Axxxb/VEGF-Axxx ratio was also
observed at the mRNA level (�p<0.05; n = 4 biological repeats; T-test). D) DIAVIT inhibited angiogenesis in HUVECs
when plated on to Matrigel (�p<0.05 vs control), which was partially prevented when an antibody specific for
VEGF-A165b was added to the treatment (†p<0.05 vs DIAVIT). Measurments were taken in the form of the relative
number of branch points (Ei) and the relative tubule length (Eii) (n = 4; One-way ANOVA with Bonferroni post-hoc
test for comparison between pairs). F) Diabetic db/db mice showed switches in the spicing of VEGF-A in the kidney
cortex; VEGF-A120 and VEGF-A164 were increased relative to lean controls (Gi;
�p<0.05 and �p<0.01, VEGF-A120 and
VEGF-A164, respectively; all VEGF-A isoforms were detected on the same blot), whereas VEGF-A165b was down-
regulated (Gii; �p<0.05). Treatment of the diabetic mice with DIAVIT resulted in no significant increases in
VEGF-A120 (Gi); although no effect was observed on total VEGF-A164 expression compared to un-treated db/db mice,
DIAVIT extract to treat diabetic nephropathy
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podocytes with delphinidin (10 μg/ml) for 48 hrs resulted in a splicing switch to increase
VEGF-A165b relative to total VEGF-A165 in both normal glucose (NG) and high glucose (HG)
conditions (protein: Fig 7A, quantified in Fig 7B; p<0.05; mRNA: Fig 7D). In addition, delphi-
nidin significantly decreased the expression of total VEGF-A165 (Fig 7C; p<0.05). Therefore,
DIAVIT did cause a shift in splicing to up-regulate VEGF-A165b relative to VEGF-A164 (Gii; †p<0.05 vs diabetic;
n = 3–6 mice; One-way ANOVA with Bonferroni post-hoc test for comparison between pairs). H) Diabetes did not
alter the expression of the podocyte marker and transcription factor WT1. However, DIAVIT did result in an increase
in WT1 expression in the kidney cortex of db/db mice (I) (�p<0.05; n = 4 mice; One-way ANOVA with Bonferroni
post-hoc test for comparison between pairs).
https://doi.org/10.1371/journal.pone.0212910.g005
Fig 6. Diabetic mice develop an increase in the activation of pro-angiogenic and pro-fibrotic factors in the kidney,
which is prevented with DIAVIT treatment. A) Western blotting of protein extracted from the kidney cortex shows
an increased phosphorylation and expression of AktSer473 (A, B), an increase in the phosphorylation and expression of
ERK1/2 (a, c), and an increase in the expression of COX-2 in diabetic db/db mice (A, D; phosphorylation �p<0.01;
expression �p<0.05 vs lean). DIAVIT prevented the increased activation and expression of these factors in the diabetic
mice (A-D; †p<0.05 vs diabetic; n = 3–8 mice; all proteins were detected on the same blot). In addition, diabetic db/db
mice had an increased expression of p65-NFĸB in the kidney cortex, which was singifcantly rescued by DIAVIT
treatment (E, F; p<0.05; n = 3–4 mice; One-way ANOVA with Bonferroni post-hoc test for comparison between
pairs).
https://doi.org/10.1371/journal.pone.0212910.g006
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Fig 7. Delphinidin alters VEGF-A splicing to increase VEGF-A165b and decrease total VEGF-A expression. A)
Treatment of podocytes with delphinidin chloride (10 μg/ml) under normal glucose (NG; 5 mM glucose + 25 mM
mannitol) and high glucose (HG; 30 mM glucose, 1 ng/ml TNFα, 1 ng/ml IL-6, and 100 nM insulin) for 48 hrs
increased the protein expression of VEGF-A165b relative to total VEGF-A165 (quantified in B;
�p<0.05 vs NG, †p<0.05
vs HG; n = 3 biological repeats; One-way ANOVA with Bonferroni post-hoc test for comparison between pairs; A—
the same blot was first probed with VEGF-A165b before stripping and reprobing with panVEGF-A). C) Under both
NG and HG condition, delphinidin significantly decreased the protein expression of total VEGF-A165 (
�p<0.05; n = 3
biological repeats; One-way ANOVA with Bonferroni post-hoc test for comparison between pairs). D) Analysis at the
mRNA level shows an increase in the VEGF-Axxxb/VEGF-Axxx ratio after treatement with delphinidn (
�p<0.05; n = 4
biological repeats; T-test). E) Delphinidin inhibited angiogenesis in HUVECs when plated on to Matrigel (�p<0.05 vs
control). Addition of an antibody specific for VEGF-A165b did not alter the effect of delphinidin. Measurments were
taken in the form of the relative number of branch points (Fi) and the relative tubule length (Fii) (n = 4; One-way
ANOVA with Bonferroni post-hoc test for comparison between pairs). G) Cells pre-treated with DMSO/delphinidin
were stimulated with NG/HG for 30 or 60 mins. After 30 min, there was no significant effect of delphinidin on the
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we assessed the effects of delphinidin on angiogenesis using a Matrigel angiogenesis assay.
HUVECs were plated onto Matrigel and treated with conditioned media from podocytes pre-
treated with delphinidin for 48 hrs. Four hours later, delphinidin-treated HUVECs had a
reduction in the relative number of branch points and the relative tubule length (Fig 7E and
7F; �p<0.05), compared to DMSO treated controls. This anti-angiogenic effect was not signifi-
cantly reversed when the podocytes and HUVECs were treated with delphinidin and an anti-
body specific for the VEGF-A165b isoform.
To determine the mechanism of the effect of delphinidin on VEGF-A splicing, we analysed
the phosphorylation of SRSF6 (resulting in VEGF-A165b expression) and SRSF1 (resulting in
VEGF-A165 expression) in NG and HG conditions. We found that after 60 min, delphinidin
significantly increased the phosphorylation of SRSF6 in HG conditions (Fig 7G, quantified
in Fig 7H; p<0.05). Delphinidin had no effect on the phosphorylation of SRSF1 in either
condition.
Discussion
This study provides evidence that DIAVIT, a natural drug containing blueberry and sea buck-
thorn, is protective in a type II mouse model of DN. In this study, DIAVIT prevented the
increased permeability of the GFB, fibrosis in the kidney cortex, and an endothelial insult in
type II diabetic mice. Mechanistically, DIAVIT is likely to be affecting multiple pathways as it
is comprised of hundreds of compounds. However, with regards to microcirculation/perme-
ability and fibrosis, DIAVIT switched the splicing of VEGF-A to increase the expression of the
anti-angiogenic VEGF-A165b, and reduced the activation of pro-inflammatory and pro-
fibrotic markers. Furthermore, the most abundant anthocyanin in DIAVIT, delphinidin, was
found to modulate VEGF-A expression and splicing through the activation of SRSF6. This
resulted in an anti-angiogenic effect through up-regulation of the anti-angiogenic VEG-
F-A165b, but a reduction in the expression of total VEGF-A.
With increasing evidence to suggest that DN is driven by microvessel damage and increased
permeability, fibrosis, and inflammation, recent developments have focused on therapeutic
factors that prevent the up-regulation of these pathways [7,17,18]. VEGF-A is widely accepted
to be involved in the vascular complications related to diabetes; however, the alternative splice
isoform VEGF-A165b has recently proven to be therapeutically beneficial in both type I and
type II models of DN [7]. In addition, switches in VEGF-A splicing to up-regulate the VEG-
F-Axxxb (xxx denotes the number of amino acids) isoforms have also been shown to have anti-
angiogenic, and therefore therapeutic, effects in models of retinopathy and cancer [29,30]. To
our knowledge, this is the first report to suggest an anthocyanin present in a natural drug can
switch VEGF-A splicing to promote the expression of the anti-angiogenic VEGF-A165b both
in the mouse kidney cortex and in conditionally immortalized podocytes. Over-expression of
just the VEGF-A165b isoform in the podocytes of mice has no detrimental effects on kidney
function [31]. Furthermore, over-expression of podocyte-specific VEGF-A165b when all other
isoforms of VEGF-A are depleted results in a rescue of the glomerular injury phenotype [12].
We show that in db/db mice the splicing and expression of VEGF-A are altered to increase the
pro-angiogenic VEGF-A164 and decrease the anti-angiogenic VEGF-A165b, which is consistent
with what is reported in human diabetic nephropathy [7]. However, DIAVIT partially prevents
phosphorylation of SRSF6 or SRSF1 under either condition (H). After 60 min, delphinidin significantly increased the
phosphorylation of SRSF6 after stimulation with HG (�p<0.05 vs NG and HG controls; n = 3 biological repeats; One-
way ANOVA with Bonferroni post-hoc test for comparison between pairs). There was no significant effect on
phospho-SRSF1 at 60 min.
https://doi.org/10.1371/journal.pone.0212910.g007
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this switch in splicing, resulting in an increase in the VEGF-A165b/VEGF-A164 ratio in the dia-
betic mice (Fig 5E). We hypothesize that this switch in splicing contributed to the therapeutic
phenotype induced by DIAVIT, including preventing increases in albuminuria and glomerular
water permeability (Fig 1), glomerular fibrosis (Fig 2), and the ultra-structural changes to the
mesangial cells, endothelial cells, GBM, and podocyte foot processes (Fig 4), which have previ-
ously been shown to be rescued by VEGF-A165b treatment in models of DN and kidney disease
[7,12].
VEGF-A165b has been reported to increase the glomerular endothelial cell VEGFR2 expres-
sion [7,12]. We show a similar result; the kidney cortex expression of VEGFR2 is decreased in
diabetic mice, which is rescued to expression levels higher than the lean controls in db/db +
DIAVIT mice (Fig 3F). This is likely to be in part due to the increased expression of VEGF-
A165b in the DIAVIT-treated mice. Although VEGF-A165b increases the expression of
VEGFR2, it inhibits signalling by preventing receptor phosphorylation, as previously shown in
HUVECs [30], and ciGEnCs [12]. As a result, the activation of pro-angiogenic and pro-perme-
ability proteins downstream of VEGFR2, such as Akt and ERK1/2, are inhibited [32]. We see a
similar result in this study; diabetic mice treated with DIAVIT have reduced phosphorylation
and expression of Akt and ERK1/2 compared to diabetic controls (Fig 6A).
Furthermore, activation of Akt has been previously reported to result in the auto-phosphor-
ylation of serine/threonine-protein kinase 1 (SRPK1), an SR protein kinase responsible for
phosphorylating SRSF1, which promotes proximal splice site selection in exon 8 of VEGF-A
and thus increases the expression of the pro-angiogenic VEGF-Axxx isoforms [33]. WT1 is an
inhibitor of SRPK1 phosphorylation; Denys Drash Syndrome patients have a mutation in
WT1, resulting in no inhibition of SRPK1 and an increased VEGF-A165/VEGF-A165b ratio
[29]. However, the WT1-SRPK1 signaling pathway is not the only pathway known to regulate
VEGF-A splicing; SRSF6, which promotes distal splice site selection in exon 8 of VEGF-A
(increasing VEGF-Axxxb expression) has recently been shown to be down-regulated in diabe-
tes [34]. This may be explain why we do not see a change in WT1 expression in db/db mice rel-
ative to lean controls, even though the expression of VEGF-A165b is decreased in db/db mice.
In our study, we see an increase in the phosphorylation of Akt within the kidney cortex of dia-
betic db/db mice, which is not observed in db/db + DIAVIT mice. Furthermore, we also see an
increase in WT1 expression with DIAVIT treatment.
Although there are no reports on delphinidin, or any other anothocyanins, having an effect
on gene splicing, delphinidin is widely reported to reduce total VEGF-A expression through
the PKC/PI3K/Akt/mTOR signaling pathways, without having any effect on the p38MAPK
pathway [24,25]. Previous studies on VEGF-A splicing have shown that upregulation of the
PKC pathway results in SRSF1 phosphorylation and proximal splice site selection in exon 8 of
VEGF-A, whereas upregulation of the p38MAPK signalling pathways instead induces SRSF6
phosphorylation promoting distal splice site selection [35]. The present study confirms these
findings at the level of VEGF-A splicing regulation; delphinidin induced the phosphorylation
of SRSF6 but not SRSF1 in podocytes, resulting in an increase in VEGF-A165b relative to
VEGF-A165. Together, this data suggests that DIAVIT, including delphinidin present in DIA-
VIT, is increasing the VEGF-A165b/VEGF-A165 ratio through the inhibition of Akt, up-regula-
tion of WT1, and increased phosphorylation of SRSF6.
In addition, we show that delphinidin results in a down-regulation of pro-angiogenic
VEGF-A expression, resulting in the inhibition of angiogenesis (Fig 7D), as reported in multi-
ple studies assessing the effects of delphinidin on VEGF-A expression [24,25]. Although the
anti-angiogenic effect of DIAVIT was reversed when anti-VEGF-A165b was added to the
Matrigel assay, leading us to conclude that the total anti-angiogenic effect of DIAVIT was par-
tially the result of alternative splicing, there was no significant reversal of the inhibition of
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angiogenesis by delphinidin with anti-VEGF-A165b. We clearly show that delphinidin pro-
motes VEGF-A165b expression relative to VEGF-A165; however, delphinidin also has an inhibi-
tory effect on VEGF-A total expression, which is not observed in response to the DIAVIT
extract. Therefore, we postulate that although delphinidin induces a splicing switch to promote
the anti-angiogenic VEGF-A isoform expression, it is the inhibitory effect on VEGF-A expres-
sion that is the main factor contributing to its anti-angiogenic effect. Furthermore, delphinidin
has been previous reported to be cytoprotective to endothelial function [36]. This may explain
why we see a reno-protective effect of DIAVIT without any effect on blood glucose levels.
In DN, glucotoxicity results in the increased generation of free radicals and oxidative stress
[15]. Activation of NFĸB is widely reported to be evoked by increased oxidative stress [16].
Previous studies in rodent models of DN have indicated that a reduction in oxidative stress
using anti-oxidants, such as those found in red berry extracts, resulted in decreased NFĸB
activity, thus improving kidney function [17,18]. We show that DIAVIT prevented the
increases in NFĸB expression within the kidney cortex of db/db mice, resulting in an inhibi-
tion of glomerular fibrosis and endothelial injury (Fig 6G). Furthermore, anothocyanins have
been reported to protect against fibrosis, angiogenesis, and inflammation in the kidneys of dia-
betic animal models [37,38]. We summarize the potential mechanism of action of DIAVIT
and delphinidin in DN using a flow diagram in Fig 8.
Fig 8. Flow diagram describing the potential mechanism of DIAVIT and Delphinidin in type II DN. High
glucose and an increase in oxidative stress (ROS; reactive oxygen species) in the kidney results in increased
phosphorylation of Akt. In turn this leads to activation of p65-NFĸB, resulting in the increased expression of pro-
angiogenic and pro-fibrotic factors, which feed back to further increase the activation of Akt. Akt activation also results
in the phosphorylation of serine protein kinase 1 (SRPK1), leading to proximal splice site (PSS) selection in exon 8 of
the VEGF-A gene (pro-angiogenic VEGF-A165). DIAVIT acts to inhibit the phosphorylation of Akt and increase the
expression of the SRPK1 inhibitor WT1. Furthermore, delphinidin acts to switch VEGF-A splicing, promoting distal
splice site selection through the activation of SRSF6. This results in a reduction in fibrosis and angiogenesis in the
diabetic kidney through p65-NFĸB and VEGF-A splicing.
https://doi.org/10.1371/journal.pone.0212910.g008
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One limitation of this study was that we were unable to fully control the dose of DIAVIT
given to the mice as it was added to the drinking water. Diabetic mice, on average, drank more
water than the lean controls; as the levels of hyperglycaemia were similar in both db/db and
db/db + DIAVIT mice, we estimated that they consumed approximately the same amount
water.
Conclusions
In conclusion, we show that DIAVIT prevents increases in permeability and fibrosis in a
mouse model of type II DN. One of the mechanisms by which DIAVIT, namely delphinidin, is
acting are through switching VEGF-A splicing in the podocytes of the renal cortex. This study
highlights the therapeutic potential of natural drugs and anthocyanins in DN through the
manipulation of gene splicing and expression. Further studies are required to further deduce
which other compound(s) in DIAVIT are having similar effects.
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